concept

TAU HYPERPHOSPHORYLATION

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TAU HYPERPHOSPHORYLATION: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

70Connections

0Hypotheses

8Analyses

16Outgoing

50Incoming

0Experiments

9Debates

No summary available yet.

View on Wiki →

No AI portrait yet

💡 Concept Info

Name	TAU HYPERPHOSPHORYLATION

Pathway Diagram

graph TD
    TAU_HYPERPHOSPHORYLATION["TAU HYPERPHOSPHORYLATION"]
    TAU_HYPERPHOSPHORYLATION -->|"contributes to"| Tau_Aggregation["Tau Aggregation"]
    TAU_HYPERPHOSPHORYLATION -->|"causes"| Alzheimer_s_disease["Alzheimer's disease"]
    MAPT["MAPT"] -->|"involved_in"| TAU_HYPERPHOSPHORYLATION
    Exendin_4["Exendin-4"] -->|"inhibits"| TAU_HYPERPHOSPHORYLATION
    ASK1["ASK1"] -->|"causes"| TAU_HYPERPHOSPHORYLATION
    Wnt___catenin_NeuroD1_Pathway["Wnt/beta-catenin/NeuroD1 Pathway"] -->|"regulates"| TAU_HYPERPHOSPHORYLATION
    Neuroinflammation["Neuroinflammation"] -->|"contributes to"| TAU_HYPERPHOSPHORYLATION
    HEPATOKINES["HEPATOKINES"] -->|"regulates"| TAU_HYPERPHOSPHORYLATION

Outgoing (16)

Target	Relation	Type	Str
Alzheimer's Disease	associated_with	disease	0.95
Neurofibrillary Tangles	causes	biomarker	0.95
Paired Helical Filaments	causes	biomarker	0.90
Synaptic Toxicity	associated_with	phenotype	0.90
Cognitive Impairments	associated_with	phenotype	0.90
Alzheimer's Disease	drives	disease	0.90
Alzheimer'S Disease	biomarker_for	disease	0.90
Tauopathies	biomarker_for	disease	0.90
Neurodegeneration	contributes_to	process	0.90
Tau Aggregation	contributes_to	process	0.85
tau O-GlcNAc protection	suppresses	process	0.85
Type 2 Diabetes	associated_with	disease	0.85
Alzheimer'S Disease	contributes_to	disease	0.85
Alzheimer's disease	causes	disease	0.70
Alzheimer's disease	causes	disease	0.70
Alzheimer's disease	associated_with	disease	0.70

Incoming (54)

Source	Relation	Type	Str
MAPT	involved_in	protein	0.95
DAB	causes	compound	0.95
GSK3B	involved_in	gene	0.95
PPP2CA	regulates	gene	0.95
Exendin-4	inhibits	drug	0.90
MAPT MUTATION	causes	gene	0.90
Sulforaphane	inhibits	compound	0.90
Ampk Activation	promotes	process	0.90
37435081	ameliorated	paper	0.90
Aβ oligomers	triggers	biomarker	0.90
GSK3B	causes	protein	0.90
CDK5	causes	protein	0.90
32057125	is an early step in and associated with	paper	0.90
GSK-3β	activates	protein	0.90
31931119	induces	paper	0.90
Air Pollution	causes	compound	0.90
32057125	is an early step in	paper	0.90
32057125	is associated with	paper	0.90
PKR	causes	entity	0.90
ASK1	mediates	protein	0.85
APOE4	risk_factor_for	gene	0.85
Tau Kinase Inhibitors	inhibits	drug	0.85
MTOR	promotes	gene	0.85
Ceramide	contributes_to	compound	0.85
Wnt/β-catenin/NeuroD1 Pathway	regulates	pathway	0.85
ASK1	causes	protein	0.85
Platelets	associated_with	cell_type	0.85
miR-132	inhibits	biomarker	0.80
miR-125b	contributes_to	biomarker	0.80
GSK3B	mediates	gene	0.80
HEPATOKINES	regulates	protein	0.80
ASK1	contributes_to	protein	0.80
Insulin Signaling	inhibits	pathway	0.80
Neuroinflammation	contributes_to	process	0.80
IL-6	causes	protein	0.70
GSK3B	regulates	gene	0.70
GSK3β	activates	protein	0.70
CDK5	regulates	gene	0.70
p25/CDK5 hyperactivity	causes	mechanism	0.70
GSK-3	regulates	protein	0.70
BACE1	causes	gene	0.70
Ramalin	suppresses	gene	0.70
GSK3β	causes	protein	0.70
CDK5	causes	protein	0.70
IL-1β signaling	accelerates	pathway	0.70
PI3K	inhibits	gene	0.70
MTOR	activates	protein	0.70
BMAL1	protects_against	gene	0.70
Exendin-4	inhibits	drug	0.70
Indoles	protects_against	process	0.70

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (8)

Scientific analyses that reference this entity

Test Preregistration Analysis

neurodegeneration | 2026-04-27 | 7 hypotheses Top: 0.710

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

neurodegeneration | 2026-04-26 | 7 hypotheses Top: 0.585

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.629

How does APOE4's beneficial immune function reconcile with its established role

neurodegeneration | 2026-04-12 | 1 hypotheses Top: 0.575

Is HCN1 dysfunction causal or protective in EC layer II neurodegeneration?

neurodegeneration | 2026-04-12 | 0 hypotheses

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (9)

Multi-agent debates referencing this entity

Test question for preregistration

active · Rounds: 4 · Score: 0.77 · 2026-04-28

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

closed · Rounds: 4 · Score: 1.00 · 2026-04-26

While single-cell sequencing reveals microglial heterogeneity across regions, ag

closed · Rounds: 4 · Score: 0.73 · 2026-04-22

The abstract mentions that pathological seeds have different characteristics and

closed · Rounds: 4 · Score: 0.65 · 2026-04-21

The debate revealed a fundamental gap in understanding whether tau pathology dir

closed · Rounds: 4 · Score: 0.30 · 2026-04-21

What is the current clinical trial landscape for AD therapeutics, and which mech

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

Is the amyloid concentration in AD clinical trials rational given lecanemab's ap

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

The debate revealed conflicting evidence about whether HCN1 downregulation drive

closed · Rounds: 4 · Score: 0.93 · 2026-04-16

How does APOE4's beneficial immune function reconcile with its established role

closed · Rounds: 4 · Score: 0.78 · 2026-04-12

Related Research

Hypotheses and analyses mentioning TAU HYPERPHOSPHORYLATION in their description or question text

No additional research found

TAU HYPERPHOSPHORYLATION

Understanding Entity Pages

Pathway Diagram

Outgoing (16)

Incoming (54)

Targeting Hypotheses (0)

Mentioning Analyses (8)

Test Preregistration Analysis

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

How does APOE4's beneficial immune function reconcile with its established role

Is HCN1 dysfunction causal or protective in EC layer II neurodegeneration?

Does tau aggregation specifically cause PS externalization in vesicles independe

What molecular mechanisms determine the conformational diversity and strain-like

How do regional, age, and sex-dependent differences in microglial populations af

Experiments (0)

Related Papers (0)

Debates (9)

Test question for preregistration

Can CSF p-tau217 normalization serve as a reliable surrogate endpoint for determ

While single-cell sequencing reveals microglial heterogeneity across regions, ag

The abstract mentions that pathological seeds have different characteristics and

The debate revealed a fundamental gap in understanding whether tau pathology dir

What is the current clinical trial landscape for AD therapeutics, and which mech

Is the amyloid concentration in AD clinical trials rational given lecanemab's ap

The debate revealed conflicting evidence about whether HCN1 downregulation drive

How does APOE4's beneficial immune function reconcile with its established role

Related Research